These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22043301)

  • 1. Survival outcomes and effect of early vs. deferred cART among HIV-infected patients diagnosed at the time of an AIDS-defining event: a cohort analysis.
    Miro JM; Manzardo C; Mussini C; Johnson M; d'Arminio Monforte A; Antinori A; Gill MJ; Sighinolfi L; Uberti-Foppa C; Borghi V; Sabin C;
    PLoS One; 2011; 6(10):e26009. PubMed ID: 22043301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy--the CASCADE collaboration: a collaboration of 23 cohort studies.
    Wolbers M; Babiker A; Sabin C; Young J; Dorrucci M; Chêne G; Mussini C; Porter K; Bucher HC;
    PLoS Med; 2010 Feb; 7(2):e1000239. PubMed ID: 20186270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study.
    ; Judd A; Chappell E; Turkova A; Le Coeur S; Noguera-Julian A; Goetghebuer T; Doerholt K; Galli L; Pajkrt D; Marques L; Collins IJ; Gibb DM; González Tome MI; Navarro M; Warszawski J; Königs C; Spoulou V; Prata F; Chiappini E; Naver L; Giaquinto C; Thorne C; Marczynska M; Okhonskaia L; Posfay-Barbe K; Ounchanum P; Techakunakorn P; Kiseleva G; Malyuta R; Volokha A; Ene L; Goodall R
    PLoS Med; 2018 Jan; 15(1):e1002491. PubMed ID: 29381702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE.
    ; Young J; Psichogiou M; Meyer L; Ayayi S; Grabar S; Raffi F; Reiss P; Gazzard B; Sharland M; Gutierrez F; Obel N; Kirk O; Miro JM; Furrer H; Castagna A; De Wit S; Muñoz J; Kjaer J; Grarup J; Chêne G; Bucher H
    PLoS Med; 2012; 9(3):e1001194. PubMed ID: 22448150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
    Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
    HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Markov model for the effects of virological failure on HIV/AIDS progression in tuberculosis co-infected patients receiving antiretroviral therapy in a rural clinic in northern South Africa.
    Shoko C; Chikobvu D; Bessong PO
    S Afr Med J; 2020 Mar; 110(4):313-319. PubMed ID: 32657744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
    ; Sterne JA; May M; Costagliola D; de Wolf F; Phillips AN; Harris R; Funk MJ; Geskus RB; Gill J; Dabis F; Miró JM; Justice AC; Ledergerber B; Fätkenheuer G; Hogg RS; Monforte AD; Saag M; Smith C; Staszewski S; Egger M; Cole SR
    Lancet; 2009 Apr; 373(9672):1352-63. PubMed ID: 19361855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial.
    Zolopa A; Andersen J; Powderly W; Sanchez A; Sanne I; Suckow C; Hogg E; Komarow L
    PLoS One; 2009; 4(5):e5575. PubMed ID: 19440326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries.
    ; Lodi S; del Amo J; Moreno S; Bucher HC; Furrer H; Logan R; Sterne J; Pérez-Hoyos S; Jarrín I; Phillips A; Olson A; van Sighem A; Reiss P; Sabin C; Jose S; Justice A; Goulet J; Miró JM; Ferrer E; Meyer L; Seng R; Vourli G; Antoniadou A; Dabis F; Vandenhede MA; Costagliola D; Abgrall S; Hernán MA
    AIDS; 2014 Oct; 28(16):2461-73. PubMed ID: 25265230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.
    ; Cain LE; Logan R; Robins JM; Sterne JA; Sabin C; Bansi L; Justice A; Goulet J; van Sighem A; de Wolf F; Bucher HC; von Wyl V; Esteve A; Casabona J; del Amo J; Moreno S; Seng R; Meyer L; Perez-Hoyos S; Muga R; Lodi S; Lanoy E; Costagliola D; Hernan MA
    Ann Intern Med; 2011 Apr; 154(8):509-15. PubMed ID: 21502648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.
    Lapadula G; Cozzi-Lepri A; Marchetti G; Antinori A; Chiodera A; Nicastri E; Parruti G; Galli M; Gori A; Monforte Ad;
    AIDS; 2013 Mar; 27(5):769-79. PubMed ID: 23719349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher Risk of Mortality and Virologic Failure in HIV-Infected Patients With High Viral Load at Antiretroviral Therapy Initiation: An Observational Cohort Study in Chongqing, China.
    Zhou C; Zhang W; Lu R; Ouyang L; Xing H; Shao Y; Wu G; Ruan Y
    Front Public Health; 2022; 10():800839. PubMed ID: 35186841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of deaths, AIDS-defining and non-AIDS defining events among Ghanaians on long-term combination antiretroviral therapy.
    Sarfo FS; Sarfo MA; Norman B; Phillips R; Bedu-Addo G; Chadwick D
    PLoS One; 2014; 9(10):e111400. PubMed ID: 25340766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study).
    Schäfer G; Hoffmann C; Arasteh K; Schürmann D; Stephan C; Jensen B; Stoll M; Bogner JR; Faetkenheuer G; Rockstroh J; Klinker H; Härter G; Stöhr A; Degen O; Freiwald E; Hüfner A; Jordan S; Schulze Zur Wiesch J; Addo M; Lohse AW; van Lunzen J; Schmiedel S;
    AIDS Res Ther; 2019 Nov; 16(1):34. PubMed ID: 31729999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of antiretroviral therapy initiation and treatment outcomes for people living with HIV in Vietnam.
    Tran DA; Shakeshaft A; Ngo AD; Mallitt KA; Wilson D; Doran C; Zhang L
    HIV Clin Trials; 2013; 14(1):21-33. PubMed ID: 23372112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus infection in HIV-infected versus non-infected infants and HIV disease progression in Cytomegalovirus infected versus non infected infants early treated with cART in the ANRS 12140-Pediacam study in Cameroon.
    Kfutwah AK; Ngoupo PA; Sofeu CL; Ndongo FA; Guemkam G; Ndiang ST; Owona F; Penda IC; Tchendjou P; Rouzioux C; Warszawski J; Faye A; Tejiokem MC
    BMC Infect Dis; 2017 Mar; 17(1):224. PubMed ID: 28335737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.
    Guiguet M; Boué F; Cadranel J; Lang JM; Rosenthal E; Costagliola D;
    Lancet Oncol; 2009 Dec; 10(12):1152-9. PubMed ID: 19818686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS Cohort.
    Manzardo C; Esteve A; Ortega N; Podzamczer D; Murillas J; Segura F; Force L; Tural C; Vilaró J; Masabeu A; Garcia I; Guadarrama M; Ferrer E; Riera M; Navarro G; Clotet B; Gatell JM; Casabona J; Miró JM;
    Clin Microbiol Infect; 2013 Jul; 19(7):646-53. PubMed ID: 22967234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002.
    Lampe FC; Gatell JM; Staszewski S; Johnson MA; Pradier C; Gill MJ; de Lazzari E; Dauer B; Youle M; Fontas E; Krentz HB; Phillips AN
    Arch Intern Med; 2006 Mar; 166(5):521-8. PubMed ID: 16534038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disparities in Initiation of Combination Antiretroviral Treatment and in Virologic Suppression Among Patients in the HIV Outpatient Study, 2000-2013.
    Novak RM; Hart RL; Chmiel JS; Brooks JT; Buchacz K;
    J Acquir Immune Defic Syndr; 2015 Sep; 70(1):23-32. PubMed ID: 25886926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.